Rilzabrutinib Yields Responses in Angioedema in People With CS Urticaria
Tackling Chronic Spontaneous Urticaria: Emerging Treatment Horizons Recent developments in the management of chronic spontaneous urticaria (CSU) underscore a pivotal shift in treatment paradigms. A study presented at the 2025 American Academy of Allergy, Asthma, and Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress highlighted the therapeutic potential of rilzabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor. … Read more